Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Phys Written Answerspharmacological

Phys Written Answers · pharmacological

Cardiac Glycoside — Written Clinical Reasoning

DCE-style written reasoning for Cardiac Glycoside.

On this page & tools

Target exams

FRACP DCEMRCP Part 2

Target exams

FRACP DCEMRCP Part 2
Prompt
DCE-style written reasoning for Cardiac Glycoside.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Cardiac Glycoside and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

  1. [1]Kumar A, Ul Haque Z, Rai A Evaluation of the Therapeutic Potential and Safety of Terminalia arjuna in Heart Failure Management: A Systematic Review and Meta-analysis of Randomized Controlled Trials Ann Afr Med, 2026.PMID 42389976
  2. [2]Ecker PAM, Schaper A, Bräunig HJ, Seifert R Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin Eur J Clin Pharmacol, 2026.PMID 42334625
  3. [3]Maroyi A Evaluation of Medicinal Uses, Phytochemistry and Biological Activities of Combretum vendae A.E. Van Wyk (Combretaceae) Pak J Biol Sci, 2026.PMID 42316833
  4. [4]Mehra MR, Vukicevic M, Desai AS Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration J Card Fail, 2026.PMID 42331138
  5. [5]Bavendiek U, Bauersachs J [Digitalis and Heart Failure] Dtsch Med Wochenschr, 2026.PMID 42214363
  6. [6]Jerical C, Ahmed E, Asifa S, Ariba S, et al. Therapeutic Impact of Cardiac Glycosides (Digoxin and Digitoxin) in Heart Failure With Reduced Ejection Fraction: A Systematic Review Cardiol Rev, 2026.PMID 42132739
  7. [7]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
  8. [8]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005